摘要
背景:近几十年来,随着抗生素的滥用,细菌耐药性不断增强。越来越多的超级细菌被发现,严重威胁人类健康。开发新型抗菌剂以克服耐药性是一项紧迫的任务。众所周知,阻断细菌DNA和RNA的信息传递是抑制细菌生长的有效途径之一。因此,作为DNA复制和转录必不可少的酶,DNA促旋酶是细菌抑制剂的重要靶点之一。因此,还开发了许多DNA促旋酶抑制剂。 方法:在这篇综述中,为了突出 DNA 促旋酶抑制剂的最新进展,根据其骨架或核心部分总结和组织了过去三年(2017-2019)该领域的研究。 DNA促旋酶的两个亚基都被考虑在内。 结果:这些 DNA 促旋酶抑制剂已根据其骨架或核心部分进行分类。经过对划分的14个类别的比较,我们可以为以后的修改找到一些线索。特别是,我们发现苯二氮卓类和萘杂环是药物设计中最常见的结构。另一方面,异丙基和环丙基也被用于药物设计,这为研究提供了更多的灵感。除了 GSK2140944 已进入 III 期临床试验阶段,这里的其他化合物并未完全公布其最佳药代动力学活性。 结论:我们简要总结了该主题的现状和未来挑战。通过对设计策略和药物效应的讨论,我们希望这篇综述能为未来的研究提供一个重点方向。
关键词: 抗菌、DNA促旋酶、抑制活性、氟喹诺酮、环丙沙星、药效、细菌耐药性。
Current Medicinal Chemistry
Title:Recent Progress in Small Molecular Inhibitors of DNA Gyrase
Volume: 28 Issue: 28
关键词: 抗菌、DNA促旋酶、抑制活性、氟喹诺酮、环丙沙星、药效、细菌耐药性。
摘要:
Background: In the past few decades, with the abuse of antibiotics, bacterial resistance has enhanced constantly. More and more super species of bacteria, which are seriously threatening human health, have been discovered. Developing novel antibacterial agents to overcome the drug-resistance is an urgent duty. We all know that blocking the information-transfer of bacterial DNA and RNA is one of the effective ways to inhibit bacterial growth. Therefore, as the indispensable enzyme for DNA replication and transcription, DNA gyrase is one of the important targets for bacterial inhibitors. Accordingly, many inhibitors of DNA gyrase have also been developed.
Methods: In this review, to highlight the recent progress in DNA gyrase inhibitors, the study in this field over the past three years (2017-2019) was summarized and organized based on their backbones or core moieties. Both of the subunits of DNA gyrase were taken into consideration.
Results: These DNA gyrase inhibitors have been classified based on their backbones or core moieties. After the comparison of the divided 14 categories, we could achieve some clues for future modification. In particular, we found that benzodiazepines and naphthalene heterocycles were the most common structures in the drug design. On the other hand, isopropyl and cyclopropyl have also been used in drug design, which provides more inspiration for the investigations. Except for GSK2140944, which has entered the phase III clinical trial stage, other compounds here were not fully promulgated with their optimal pharmacokinetic activity.
Conclusion: We briefly summed up the current situation and future challenges on this topic. Through the discussion of the design strategies and drug effect, we hope that this review can provide a focused direction for future researches.
Export Options
About this article
Cite this article as:
Recent Progress in Small Molecular Inhibitors of DNA Gyrase, Current Medicinal Chemistry 2021; 28 (28) . https://dx.doi.org/10.2174/1871529X21666210202113128
DOI https://dx.doi.org/10.2174/1871529X21666210202113128 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics
Recent Patents on Anti-Cancer Drug Discovery The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Chronic Inflammatory-Modulating Potential of <i>Cassia auriculata</i> with Proinflammatory Cytokine IL-1beta and Its Anticancer Effect on Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews The Prognosis and Treatment of Adult Acute Leukemia with 11q23/MLL According to the Fusion Partner
Current Cancer Therapy Reviews Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry The HIV-1 Tat Protein: A Multifaceted Target for Novel Therapeutic Opportunities
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Recent Progress in the Development of Synthetic Hybrids of Natural or Unnatural Bioactive Compounds for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
Current Stem Cell Research & Therapy Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry